KALV250117P2500
- 0.00
- 0.000.00%
KalVista Pharmaceuticals Newsroom
Sector Update: Health Care Stocks Advance in Afternoon Trading
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
KalVista Wins New Buy at BofA on Potential of Lead Candidate
BofA Securities Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $22
B of A Securities Initiates Coverage On KalVista Pharma With Buy Rating, Announces Price Target of $22
Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Express News | Kalvista Appoints Jeb Ledell as Chief Operating Officer
KalVista Appoints Jeb Ledell As Chief Operating Officer >KALV
KalVista Appoints Jeb Ledell as Chief Operating Officer
Optimistic Buy Rating for KalVista Pharmaceuticals: Strategic Financial Moves and Promising Drug Launch Bolster Market Potential
Cantor Fitzgerald Reiterates Overweight on KalVista Pharmato Overweight
Express News | Kalvista Pharmaceuticals Inc : Jefferies Cuts Target Price to $33 From $35
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $33
KalVista Pharmaceuticals Set for Success With Sebetralstat's Promising FDA Review and Strong Financial Backing
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
KalVista Pharmaceuticals Reports Progress in HAE Treatment
KalVista Pharmaceuticals | 8-K: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals | 10-Q: Q2 2025 Earnings Report